Zydus Cadila starts phase 2 clinical trial in NAFLD
Zydus Cadila starts phase 2 clinical trial in NAFLD

Zydus Cadila starts phase 2 clinical trial in NAFLD

Apurva Joshi Article rating: 4.5

Zydus Cadila announced on Wednesday that it has initiated a Phase 2 clinical trial for gauging the effect of Saroglitazar Mg in the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) in women suffering with polycystic ovary syndrome (PCOS). The EVIDENCES VII trial is currently recruiting patients across several clinical sites in USA and Mexico.

Ten stocks close to their 52-weeks high
Ten stocks close to their 52-weeks high

Ten stocks close to their 52-weeks high

Anupama Pattanaik Article rating: 5.0
The markets on August 21, 2019 opened gap down. BSE Sensex is trading at 37,130.56, down by 197.45 points and the Nifty is trading at 10,944.15, down by 72.85 points.
Alembic Pharma rises on successful inspection at Bioequivalence facility
Alembic Pharma rises on successful inspection at Bioequivalence facility

Alembic Pharma rises on successful inspection at Bioequivalence facility

Amir Shaikh Article rating: 5.0

Gujarat-based pharmaceutical company Alembic Pharma informed the bourses on Wednesday that US Food & Drug Administration (USFDA) has successfully completed inspection at its Bioequivalence facility located at Vadodara.

Personal finance rules that one should follow
Personal finance rules that one should follow

Personal finance rules that one should follow

Henil Shah Article rating: 4.5

Whether it is your investment or your financial goals, there are certain personal finance rules that one should follow to get the most out of it. What are those rules? Let’s find out.

Risk Tolerance Revealed
Risk Tolerance Revealed

Risk Tolerance Revealed

Shashikant Singh Article rating: 5.0

Risk as a concept is not understood by many and they believe risks to be same as loss. Read on to find the difference between the two.

Five stocks with selling interest
Five stocks with selling interest

Five stocks with selling interest

Anupama Pattanaik Article rating: 3.0

Overall volumes in futures & options currently stand at 1,64,89,491 contracts with a turnover of Rs. 10,69,260.44 crore.

RSS
First30723073307430753077307930803081Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR